Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR T) therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022. As a result, the Company’s total number of voting rights is now 24,962,331.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on 25 May 2022 following the Double Voting Rights:
| Total amount of share capital (EUR) | 78,584,224.33 |
| Total Number of shares with single voting rights | 20,225,581 |
| Total Number of shares with double voting rights | 2,368,375 |
| Total Number of Shares | 22,593,956 |
| Total of voting rights | 24,962,331 |
| Total number of attributed warrants | 1,997,190 |
| Total number of shares with voting rights that could be created following the exercise of the attributed warrants | 1,997,190 |
| Total number of diluted shares (Outstanding shares + Warrants) | 24,591,146 |
| Total number of diluted shares with voting rights | 26,959,521 |
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.
Further questions about the content of this release can be sent to investors@celyad.com.
About Celyad Oncology
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
Investor and Media Contacts:
Sara Zelkovic
Communications & Investor Relations Director
Celyad Oncology
investors@celyad.com
